Selby, Peter
Voci, Sabrina
Zawertailo, Laurie
Baliunas, Dolly
Dragonetti, Rosa
Hussain, Sarwar
Funding for this research was provided by:
Ontario Ministry of Health and Long-Term Care (HLTC5047FL)
Article History
Received: 28 March 2018
Accepted: 3 September 2018
First Online: 14 September 2018
Ethics approval and consent to participate
: Ethical approval was obtained from the Research Ethics Board at the Centre for Addiction and Mental Health (#081/2005). All participants provided written informed consent at the start of the workshop, prior to the presentation or dispensing of NRT.
: Not applicable.
: PS reports grants from Pfizer Inc./Pfizer Canada, Bhasin Consulting Fund, Shoppers Drug Mart and Patient-Centered Outcomes Research Institute; has received honoraria for speaking engagements from Pfizer Canada Inc., ABBVie, and Bristol-Myers Squibb; and has also received consulting fees from Pfizer Inc./ Pfizer Canada, Evidera Inc., Johnson & Johnson Group of Companies, Medcan Clinic, Miller Medical Communications, MedPlan Communications, NVision Insight Group, Inflexxion Inc., V-CC Systems Inc., Kataka Medical Communications, Sun Life Financial, and Myelin & Associates. Through an open tender process, Johnson & Johnson, Novartis, and Pfizer Inc. are vendors of record for providing smoking cessation pharmacotherapy, free or discounted, for research studies in which PS and LZ are the principal investigator or co-investigator. LZ and DB report grant funding from Pfizer Inc. through their Global Research Awards in Nicotine Dependence (GRAND). SV, RD and SH have no competing interests to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.